An interventional study of Daily Avocado Consumption in Telomere Length and Breast Cancer Females, sponsored by Institut Investigacio Sanitaria Pere Virgili. Recruiting at 1 site in Spain. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-12.
Sponsored by Institut Investigacio Sanitaria Pere Virgili · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 905 studies in Breast Neoplasms with a site in Spain — 164 open to participants now, 285 under way, 84 of them phase 3. Breast Neoplasms · Spain.
Among the 905 studies in Breast Neoplasms with a site in Spain, this one is the 449th largest by planned enrollment of the 805 interventional ones that give a count, is one of 27 that started in 2026, is one of 146 with no phase, reaches primary completion later than 140 of the 284 other live ones, and was the 855th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →164 of the 905 studies in Breast Neoplasms with a site in Spain are open now. Recruiting first, the newest first:
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia · Sites in Spain
Ages 18+
Spanish Breast Cancer Research Group · Sites in Spain
Ages 18+
Daiichi Sankyo · Sites in Spain, United States, Belgium and 5 more countries
Ages 18+
Kenko Imalytics S.L. · Sites in Spain
Ages 18+ · Women only
Spanish Breast Cancer Research Group · Sites in Spain
Ages 18+ · Women only
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 40 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
905 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 174 · Phase 2 327 · Phase 3 224 · Phase 4 13
First in 1996; this study’s year is marked. 27 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 151 across the 805 interventional studies, 200 across the 97 observational. Of the 576 that completed or were terminated, 291 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
533 of 905 have an industry lead sponsor. The 10 most frequent:
Institut Investigacio Sanitaria Pere Virgili is the lead sponsor of 39 studies on the registry; 17 are open to participants now.
Institut Investigacio Sanitaria Pere Virgili has 2 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
78 of the studies in Breast Neoplasms with a site in Spain that are under way reach primary completion within a year, 20 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03820830Phase 3ETOP IBCSG Partners FoundationPalbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer | 2026-12 |
| NCT03595592Phase 3Fondazione MichelangeloNeoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer | 2026-12-15 |
| NCT05909397Phase 3PfizerVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | 2026-12-30 |
| NCT05038735Phase 3Novartis PharmaceuticalsStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | 2027-01-28 |
| NCT04208178Phase 3Novartis PharmaceuticalsStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | 2027-02-26 |
Add all 78 to your calendar (.ics) → With an account.
Among the 905 studies in Breast Neoplasms with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Women with breast cancer are at increased risk of comorbidities and premature mortality, potentially due to accelerated biological aging. Telomere attrition has been proposed as a biomarker of this process, which could be mitigated through interventions targeting behavioral factors such as diet. In recent years, avocado has drawn attention in nutritional research due to its unique nutritional profile.
Main objective: To evaluate the effect of consuming one avocado per day on biological aging-measured by telomere length-in breast cancer survivors, compared to a habitual diet (less than two avocados per week). Secondary objectives include changes in telomerase activity and biomarkers of inflammation and oxidative stress. Additional objectives include classical cardiovascular disease markers (glucose metabolism, lipid profile, blood pressure); anthropometric measurements; symptoms of depression and anxiety; quality of life and fatigue; and diet quality.
Methodology: A randomized controlled parallel-group trial involving 120 breast cancer survivors. Participants will be randomly assigned to either the intervention group (one avocado per day) or the control group (habitual diet with fewer than two avocados per week) and followed for 4 months. At baseline and the end of the intervention, a general questionnaire will be administered; blood and urine samples will be collected; anthropometric and blood pressure measurements will be taken; and diet, physical activity, symptoms of depression and anxiety, quality of life, and fatigue will be assessed. Mean changes from baseline to the end of the intervention in the primary outcome (telomere length) and secondary outcomes (inflammation, oxidative stress, classical cardiovascular disease markers, anthropometric measures, symptoms of depression and anxiety, quality of life, and diet) will be compared between the intervention and control groups using linear regression models.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to the intervention group will be advised to follow their usual diet and to consume one avocado per day for the next four months. To ensure and facilitate compliance with the intervention, we will provide a leaflet with some recipes for incorporating avocados into their regular diet. Avocados will be provided for free. Participants will pick up avocados every two weeks from the study site.
Other: Daily Avocado Consumption
Participants allocated to the control group will be advised to follow their usual diet. Avocado consumption will not be encouraged.
Participants follow their usual diet and consume one avocado per day for 4 months
Change from baseline in leukocyte telomere length
Telomere length (TL) analysis will be performed employing the traditional real-time PCR(1) method (Cawthon 2009) by the QuantiTect Syber Green PCR kit (Qiagen). This approach employs the 36B4R single-copy gene as a reference for each sample. The measurements will be performed on a monochrome multiplex real-time quantitative PCR in a BioradCFX96 thermocycler on samples collected before and after the intervention. The data obtained by PCR will be expressed as the ratio of telomere/reference gene (T / S) as the ratio between the number of copies of the telomeric repeat (T) and a single copy gene (36B4F) (S)
Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.
Change from baseline in telomerase activity
Telomerase activity will be assessed in white blood cells (PBMCs) using the TeloTAGGG Telomerase PCR ELISAPLUS method, a photometric enzyme immunoassay for quantitative determination of telomerase activity, utilizing the Telomeric Repeat Amplification Protocol (TRAP) (Sigma Aldrich).
Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.
Change from baseline in inflammatory markers
Blood samples will be collected in the morning after 8-12h fast. Inflammatory markers (C-reactive protein, IL-1β, IL-6, TNFα, IL-8, IL-10) will be measured by commercial ELISA.
Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.
Change from baseline in oxidative markers
Blood samples will be collected in the morning after an 8-12h fast. Oxidized LDL will be measured in plasma. Spot urine will be collected, and 8-iso-prostaglandin F2α (8-isoprostanes) will be measured.
Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.
Change from baseline in fasting glucose
Fasting glucose in mg/dL will be measured by standardized methods
Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.
Change from baseline in glycated hemoglobin
glycated hemoglobin (HbA1c) in % will be measured by standardized methods
Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months
Change from baseline in insulin resistance (HOMA-IR)
Insulin resistance will be determined by HOMA-IR using plasma glucose and insulin.
Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months
Changes from baseline in lipid profile
HDL-cholesterol in mg/dL, LDL-cholesterol in mg/dL, triglycerides in mg/dL, and total cholesterol in mg/dL will be measured
Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.
Change from baseline in blood pressure
Systolic and diastolic blood pressure will be measured using an automated device, after 5minutes of resting, in triplicate with a 1-minute interval between each measurement. The first measurement will be discarded, and the average of the two other measurements will be used for analysis.
Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.
Change from baseline in body weight
Body weight in kg will be measured, with the participants wearing light clothing and no shoes, using a high-quality electronic scale
Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.
Change from baseline in waist circumference
Waist circumference in cm will be measured at the mid-point between the lowest rib and the iliac crest using an anthropometric tape
Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.
Change from baseline in BMI
Weight and height will be combined to report BMI in kg/m\^2
Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.
Change from baseline in body composition
Body composition will be assessed through TANITA
Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.
Change from baseline in the Functional Assessment of Cancer Therapy - Breast questionnaire
Quality of life will be assessed through the Functional Assessment of Cancer Therapy - Breast (FACT-B) questionnaire. It is a 37-item instrument designed to measure 5 domains (physical, social, emotional, functional well-being, and breast-cancer subscale) of health-related quality of life in patients with breast cancer. Subscale scores will be added to derive: 1. FACT-B Trial Outcome Index (TOI): ranging from 0 to 96. 2. FACT-G total score: ranging from 0 to 108 3. FACT-B total score: ranging from 0 to 148 The higher the score, the better the outcome.
Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.
Change from baseline in the Functional Assessment of Chronic Illness Therapy - Fatigue questionnaire
Fatigue will be assessed through the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) questionnaire, a 40-item measure that assesses self-reported fatigue and its impact upon daily activities and function. Subscale scores will be added to derive total scores: 1. FACIT-F Trial Outcome Index (TOI): ranging from 0 to 108 2. FACT-G total score: ranging from 0 to 108 3. FACIT-F total score: ranging from 0 to 160 4. Fatigue subscale: ranging from 0 to 52 The higher the score, the better the outcome.
Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.
Change from baseline in diet quality
Diet will be assessed using a validated semiquantitative food frequency questionnaire
Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.
Change from baseline in severity of depressive symptoms
Severity of depressive symptoms will be assessed using the self-administered Patient Health Questionnaire-9 (PHQ-9), a nine-item instrument in which each item is scored from 0 to 3, yielding a total score ranging from 0 to 27. Higher PHQ-9 scores indicate greater severity of depressive symptoms.
Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.
Change from baseline in the severity of anxiety symptoms
Severity of anxiety symptoms will be assessed using the self-administered Generalized Anxiety Disorder-7 (GAD-7) questionnaire, a seven-item instrument in which each item is scored from 0 to 3, yielding a total score ranging from 0 to 21. Higher GAD-7 scores indicate greater severity of anxiety symptoms.
Time frame: Participants will be followed for 4 months. Measurements will be done before and after 4 months.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Mar 2027, 14 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 14 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut Investigacio Sanitaria Pere Virgili